[ Synpromics raises $6.59M in Venture ]
Synpromics has raised $6.59 million in Venture.
Founded in 2010, Synpromics focuses on commercializing proprietary technology that gives biological researchers, developers and manufacturers control of gene expression through the ability to create a comprehensive portfolio of man-made DNA regulatory sequences.
The company intends to use the funds to further develop and exemplify Synpromics proprietary PromPT™ synthetic promoter design platform.
|City||Edinburgh, Edinburgh, City of|
|Founder / CEO||David C. Venables|
|Scottish Investment Bank|
|Previous Investors||Calculus Capital|